X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas: Benefits from merger - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jan 25, 2002

    Nicholas: Benefits from merger

    Nicholas Piramal India has posted a 64% jump in revenues and a 78% jump in PBT for the quarter ended December'01. This is however, due to the merger with Rhone Poulenc India and hence the results are not comparable.

    (Rs m) 3QFY01 3QFY02 % change
    Net Sales 1,181 1,931 63.5%
    Other Income 19 26 31.4%
    Expenditure 984 1,568 59.4%
    Operating Profit (EBDIT) 197 363 83.9%
    Operating Profit Margin (%) 16.7% 18.8%  
    Interest 34 84 145.6%
    Depreciation 36 44 21.2%
    Profit before Tax 146 260 78.1%
    Extraordinary Items   -52  
    Tax 12 77 540.8%
    Profit after Tax/(Loss) 134 132 -2.0%
    Net profit margin (%) 11.4% 6.8%  
    Diluted number of shares 34.9 38.0  
    Diluted Earnings per share* 14.1 13.8  
    P/E (at current price)      
    *(annualised)      

    The company recorded a 210 basis point jump in operating margins. However, interest cost has gone up sharply on account of borrowings for acquisition for Rhone-Poulenc which accounted for 80% of the borrowing cost. During the current quarter, the company incurred VRS and restructuring costs for its Bhandup plant. However, the company has changed the accounting policy with regard to writing off of VRS cost with restrospective effect from April'01. Earlier the company used to fully write off VRS expenses in the year it was incurred. However, the same would now be written off over a period of 60 months. Consequent to the above change, the charge for VRS in the current quarter is lower by Rs 260 m.

    Tax provision leapfrogged due to new accounting policy on deffered taxation. Further, the tax rebate hirtherto available to the company for its plant in backward area was no longer available. The increase in share capital is on account of shares issued to shareholders of Rhone-Poulenc India as per the merger.

    On a like to like to basis, sales have improved by around 8%, operating margins have shown a healthy improvement of 390 basis points. Profit before tax, however, registered a negative growth due to heavy rise in interest burden as explained earlier. Cash flows from sale of Rhone's property is expected to reduce interest burden going forward.

    Interest costs: Spoiling the show
    Rs m 3QFY01 3QFY02 % change
    Sales 1791 1,931 7.8%
    Operating Profit 267 363 36.2%
    Operating Profit Margin (%) 14.9% 18.8%  
    Interest 35 84 140.0%
    PBT 277 260 -6.1%

    At the current market price of Rs 225, the stock trades on a P/E of 10.7x expected earnings for FY02. The benefits due to synergies in operations, reduction in working capital requirements and savings in interest cost is expected to happen only in the next year. Valuations going forward would look attractive if the management is able to achieve a fast payback from its acquisition, as expected.

     

     

    Equitymaster requests your view! Post a comment on "Nicholas: Benefits from merger". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    PIRAMAL ENTERPRISES SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK PIRAMAL ENTERPRISES

    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON PIRAMAL ENTERPRISES

    PIRAMAL ENTERPRISES 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE PIRAMAL ENTERPRISES WITH

    MARKET STATS